HSN003839 / Beijing Pharscin InnoBio - LARVOL DELTA

Discovery of HSN003839, a highly potent inhibitor of ubiquitin-specific protease USP21 for cancer therapy (AACR 2024) - "In a preliminary mouse CDX model, monotherapy of HSN003839 showed 105% tumor growth inhibition (TGI) at 30 mg/kg with no obvious body weight reduction. Further biological characterization, efficacy and toxicity studies are ongoing.The structure of HSN003839 was not presented and will not be disclosed at the time of presentation at AACR meeting."

Oncology